The Alzheimer’s Association advised against diagnosing the disease on biomarkers alone, but other experts said the genie ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

The stock's fall snapped a two-day winning streak.

stating it "significantly undervalues" the company and does not serve shareholders' best interests. Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage ...

Goodman now anticipates that the biotechnology company will post earnings of $16.65 per share for the year, down from their prior estimate of $18.00. The consensus estimate for Biogen’s current ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...